Fenwick Represents OncoGenex Pharmaceuticals in its Definitive Agreement to Merge with Achieve Life Science

January 06, 2017

Fenwick & West represented OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a publicly held oncology biopharmaceutical company, in its definitive merger with Achieve Life Science, Inc., a privately held specialty pharmaceutical company. Upon completion of the proposed merger, Achieve’s equity holders are expected to own 75% of the combined company’s outstanding shares and current stockholders of OncoGenex are expected to own the remaining 25% of the combined outstanding shares.

The proposed merger will create a clinical-stage company focused on clinical and commercial development of cytosine, a selective nicotine receptor partial agonist currently in late-stage development for smoking cessation. More information on OncoGenex’s merger with Achieve can be obtained from the company press release.

The Fenwick transaction team included corporate lawyers Alan Smith, Kee Kim, Matthew Karwoski, Ryan McRobert, Brady Douglas and Taylor Cashwell; executive compensation and employee benefits lawyers Shawn Lampron, Glenn Borromeo, Marshall Mort, and Hans Andersson; securities lawyer Robert Freedman and Amanda Rose; technology transactions lawyers Dan Becker, Stefano Quintini, Chris Ullsperger, Phillip Decker, Sophia Chen and Amy Manning; and tax lawyers Michael Solomon and Julia Ushakova-Stein.